source
- Atea's hepatitis C combo therapy shows non-inferior results to Gilead's EpclusaAtea Pharmaceuticals announced that its oral combination of bemnifosbuvir and ruzasvir met the predefined non-inferiority criteria when compared with Gilead's Epclusa for treating hepatitis C. The…
- Trump administration ends Medicare drug plan subsidies, raising cost concerns ahead of midtermsThe White House announced that subsidies for private Medicare prescription drug plans will be discontinued, a move expected to increase premiums for many seniors. The policy shift comes as Democra…